Jul 27, 2022 8:30am EDT 180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.
Jul 21, 2022 8:00am EDT 180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering
Jun 14, 2022 4:15pm EDT 180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease
May 31, 2022 8:30am EDT 180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease
May 02, 2022 8:00am EDT REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
Apr 29, 2022 6:32pm EDT 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
Jan 31, 2022 8:00am EST 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders